Skip to main content
Bansisons Tea Industries Ltd. logo

Bansisons Tea Industries Ltd. - Investor Relations & Filings

Listed
Ticker · 519353 ISIN · INE856E01019 BSE.NS Manufacturing
Open in API
Filings indexed 269 across all filing types
Latest filing 2026-07-13 Regulatory Filings
Country IN India
Listing BSE.NS 519353 · 2 venues

Key figures FY2025

Period ended 2025-03-31 · INR
Headline annual figures for Bansisons Tea Industries Ltd., fiscal year 2025, reported in INR, with the source filing for each figure.
Total Revenues INR 480.00k per the Earnings Release filed 2025-05-29
Net Income INR -636.00k per the Earnings Release filed 2025-05-29
Total Assets INR 61.44M per the Earnings Release filed 2025-05-29
Total Equity INR 59.66M per the Earnings Release filed 2025-05-29
Cash from Ops INR -1.85M per the Earnings Release filed 2025-05-29

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Bansisons Tea Industries Ltd.

http://www.bansisontea.in

Bansisons Tea Industries Ltd. focuses on the processing, manufacturing, and distribution of diverse tea products. The company operates specialized facilities for the production of CTC and Orthodox tea varieties, emphasizing quality consistency and flavor profiles. Its operational scope includes the sourcing of raw tea leaves and the implementation of standardized processing techniques to meet the requirements of both bulk purchasers and retail markets. By leveraging technical expertise in tea production, the company provides a range of blends designed for various consumer segments. The business model centers on maintaining rigorous quality standards throughout the production cycle, from initial leaf processing to final packaging, ensuring the delivery of products that adhere to established safety and quality benchmarks.

Recent filings

Filing Released Lang Actions
Reg 74(5)
Regulatory Filings Classification · 100% confidence The document is a compliance certificate submitted by Novyra Pharmachem Limited to the BSE Limited, confirming adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This regulation requires companies to confirm the dematerialization of securities. As this is a regulatory compliance filing and not a financial report, dividend announcement, or management report, it falls under the 'Regulatory Filings' category.
2026-07-13 English
Closure of Trading Window
Regulatory Filings Classification · 100% confidence The document is a formal notification to the BSE Limited regarding the closure of the company's trading window for insiders, as required by SEBI regulations. It does not contain financial statements, earnings results, or other substantive data that would qualify it as a financial report. It is a standard regulatory compliance announcement regarding internal trading policies, which falls under the 'Regulatory Filings' category.
2026-06-26 English
Voting Results AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the voting results from an Annual General Meeting (AGM), including the Scrutinizer's Report. It explicitly references Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates the disclosure of voting results. This falls directly under the definition of 'Declaration of Voting Results & Voting Rights Announcements'.
2026-06-26 English
Proceedings of 39th AGM
AGM Information Classification · 100% confidence The document is a summary of the proceedings of the 39th Annual General Meeting (AGM) of Novyra Pharmachem Limited. It details the meeting's conduct, the items of business transacted (resolutions), and the procedural aspects of the meeting. It does not contain the final voting results (which are stated to be announced later), nor is it a proxy statement or a full annual report. It fits the definition of AGM-R (AGM Information/Materials).
2026-06-25 English
Annual Report 2025-2026
Annual Report Classification · 100% confidence The document is the '39th Annual Report' for Novyra Pharmachem Limited for the financial year 2025-2026. It contains the notice of the Annual General Meeting (AGM), the Director's Report, the Independent Auditor's Report, and the full set of audited financial statements (Balance Sheet, Profit & Loss, Cash Flow). While it includes notice of an AGM, the document is the comprehensive annual report package itself, not just a presentation or a simple notice. Therefore, it is classified as an Annual Report (10-K). FY 2026
2026-06-05 English
Annual Report 2025-2026
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal 'Notice of Thirty-Ninth Annual General Meeting' for Novyra Pharmachem Limited. It contains the agenda for the AGM, including ordinary business (adoption of financial statements, re-appointment of directors) and special business (a proposed scheme of capital reduction). While it references the financial statements and auditors' reports, it is fundamentally a proxy statement/notice sent to shareholders to solicit votes and provide information for the upcoming meeting. Therefore, it is classified as a Proxy Solicitation & Information Statement (PSI). FY 2026
2026-06-01 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.